NO20070974L - Substituerte N-acyl-2-aminotiazoler - Google Patents

Substituerte N-acyl-2-aminotiazoler

Info

Publication number
NO20070974L
NO20070974L NO20070974A NO20070974A NO20070974L NO 20070974 L NO20070974 L NO 20070974L NO 20070974 A NO20070974 A NO 20070974A NO 20070974 A NO20070974 A NO 20070974A NO 20070974 L NO20070974 L NO 20070974L
Authority
NO
Norway
Prior art keywords
aminothiazoles
acyl
substituted
diarrhea
asthma
Prior art date
Application number
NO20070974A
Other languages
English (en)
Inventor
Kevin Richard Guertin
Jianping Cai
Fariborz Firooznia
Lida Qi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35134811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20070974(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20070974L publication Critical patent/NO20070974L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84—Naphthothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen omfatter nye substituerte N-acyl-2-aminotiazoler med formel (I) hvor R, Ri og X er som definert i beskrivelsen og kravene, så vel som s farmasøytisk akseptable salter derav. Disse forbindelsene er anvendelige ved behandling av diabetes, diabetisk retinopati, astma og diaré.
NO20070974A 2004-08-05 2007-02-21 Substituerte N-acyl-2-aminotiazoler NO20070974L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59916704P 2004-08-05 2004-08-05
US68917005P 2005-06-10 2005-06-10
PCT/EP2005/008165 WO2006013054A1 (en) 2004-08-05 2005-07-28 Substituted n-acyl-2-aminothiazoles

Publications (1)

Publication Number Publication Date
NO20070974L true NO20070974L (no) 2007-03-02

Family

ID=35134811

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070974A NO20070974L (no) 2004-08-05 2007-02-21 Substituerte N-acyl-2-aminotiazoler

Country Status (16)

Country Link
US (1) US7407977B2 (no)
EP (1) EP1791822A1 (no)
JP (1) JP2008508336A (no)
KR (1) KR100874315B1 (no)
AR (1) AR050199A1 (no)
AU (1) AU2005268899B2 (no)
BR (1) BRPI0514099A (no)
CA (1) CA2575339A1 (no)
IL (1) IL180888A0 (no)
MX (1) MX2007001271A (no)
MY (1) MY140538A (no)
NO (1) NO20070974L (no)
NZ (1) NZ552650A (no)
RU (1) RU2371438C2 (no)
TW (1) TW200609228A (no)
WO (1) WO2006013054A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080406A1 (ja) * 2005-01-28 2006-08-03 Taisho Pharmaceutical Co., Ltd. 三環性化合物
WO2007134958A1 (en) 2006-05-18 2007-11-29 F. Hoffmann-La Roche Ag Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists
US8779154B2 (en) * 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
JP2011509261A (ja) * 2008-01-07 2011-03-24 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連用途向けの化合物
WO2009140621A2 (en) * 2008-05-15 2009-11-19 Duke University Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
CN114681454A (zh) * 2022-03-17 2022-07-01 江南大学 噻唑类化合物在制备抗sars-cov-2新型冠状病毒药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE744970A (fr) * 1969-01-28 1970-07-27 Lilly Co Eli Agents antiviraux et immuno-depresseurs
JPS60205454A (ja) * 1984-03-29 1985-10-17 Mitsubishi Paper Mills Ltd 電子写真感光体
CA1292226C (en) * 1986-01-16 1991-11-19 Terumi Hachiya Indenothiazole derivative and process for preparing the same
FI91859C (fi) * 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
IE68593B1 (en) * 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
TW260664B (no) * 1993-02-15 1995-10-21 Otsuka Pharma Factory Inc
DE19908537A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
EP1207155A4 (en) * 1999-07-26 2005-01-12 Shionogi & Co DRUG COMPOSITIONS HAVING AGONIST THROMBOPOIETINE ACTIVITY
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
JP2004018489A (ja) * 2002-06-19 2004-01-22 Otsuka Pharmaceut Factory Inc Ａｃａｔ−１阻害剤
SE0301885D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use IV

Also Published As

Publication number Publication date
RU2007108066A (ru) 2008-09-10
EP1791822A1 (en) 2007-06-06
JP2008508336A (ja) 2008-03-21
KR20070034124A (ko) 2007-03-27
RU2371438C2 (ru) 2009-10-27
US7407977B2 (en) 2008-08-05
KR100874315B1 (ko) 2008-12-18
US20060030589A1 (en) 2006-02-09
MY140538A (en) 2009-12-31
BRPI0514099A (pt) 2008-05-27
TW200609228A (en) 2006-03-16
MX2007001271A (es) 2007-03-21
AU2005268899B2 (en) 2009-09-24
IL180888A0 (en) 2007-07-04
NZ552650A (en) 2010-09-30
CA2575339A1 (en) 2006-02-09
AR050199A1 (es) 2006-10-04
WO2006013054A1 (en) 2006-02-09
AU2005268899A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
NO20054852L (no) GFAT inhibitorer
NO20085066L (no) 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20075626L (no) Heteroarylbenzamid-derivater for anvendelse som GLK-aktivatorer i behandling av diabetes
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
NO20080010L (no) GPCR-agonister
NO20082445L (no) Neuropeptid-2 reseptor-agonister
NO20076658L (no) Heteroarylbenzamidderivater for anvendelse som GLK aktivatorer ved behandling av diabetes
NO20085067L (no) 4,5-difenyl-pyrimidinyl substituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20082561L (no) Nye koblede pyrrolderivater
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
ATE530519T1 (de) Cyclobutylaminderivate
NO20070974L (no) Substituerte N-acyl-2-aminotiazoler
NO20070089L (no) DPP-IV inhibitorer
NO20044534L (no) Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
NO20051103L (no) Indol-3-karboksamider som Glukokinase-(GK)-Aktivatorer
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
NO20074872L (no) Pyrazoler
NO20052883L (no) Nye medikamenter for behandling av kronisk obstruktiv luftveissykdom.
DE602006019880D1 (de) Verwendung von thienopyridonderivaten als ampk-aktivatoren und pharmazeutische zusammensetzungen, die diese enthalten
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
RS52065B (en) PIPERIDINSKI GPCR AGONIST
WO2007015017A3 (fr) Nouveaux derives de polyquinoleines et leur utilisation therapeutique
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application